Emergence of high-avidity melan-a-specific clonotypes as a reflection of anti-PD-1 clinical efficacy

Cancer Research

Volumn 77, Issue 24, 2017, Pages 7083-7093

  Simon, Sylvain ^a,b   Vignard, Virginie ^a,b   Varey, Emilie ^c   Parrot, Tiphaine ^a,b   Knol, Anne Chantal ^a,b,c   Khammari, Amir ^a,b,c   Gervois, Nadine ^a,b   Lang, Francois ^a,b   Dreno, Brigitte ^a,b,c   Labarriere, Nathalie ^a,b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b LabEx IGO Immunotherapy   (France)

^c CHU Nantes ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

MELAN A; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MELANOMA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VERY ELDERLY; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; CELL CLONE; CELL CULTURE; ENZYME SPECIFICITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CELLS, CULTURED; CLONE CELLS; HUMANS; IMMUNOTHERAPY; MART-1 ANTIGEN; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; SUBSTRATE SPECIFICITY; TREATMENT OUTCOME;

EID: 85038413048     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-17-1856     Document Type: Article

References (47)

1. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 2001;98: 13866-71.
2. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 2004;574: 37-41.
3. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007;13: 1757-61.
4. Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010;7: 389-95.
5. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014;124: 2246-59.
6. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 2016;22: 433-8.
7. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeuticmodalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19: 5300-9.
8. Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015;16: 257-65.
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366: 2443-54.
10. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016;17: 1558-68.
11. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373: 23-34.
12. Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PDL1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 2015;10: e0130142.
13. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515: 568-71.
14. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515: 577-81.
15. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372: 2509-20.
16. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348: 124-8.
17. Linnemann C, van Buuren MM, Bies L, Verdegaal EME, Schotte R, Calis JJA, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 2015;21: 81-5.
18. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science 2013;339: 1546-58.
19. YoungbloodB, Oestreich KJ, HaS-J, DuraiswamyJ, Akondy RS, West EE, et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 2011;35: 400-12.
20. Youngblood B, Noto A, Porichis F, Akondy RS, Ndhlovu ZM, Austin JW, et al. Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J Immunol 2013;191: 540-4.
21. Ahn E, Youngblood B, Lee J, Lee J, Sarkar S, Ahmed R. Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. J Virol 2016;90: 8934-46.
22. Pittet MJ, Zippelius A, Valmori D, Speiser DE, Cerottini JC, Romero P. Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol 2002;23: 325-8.
23. Zippelius A, Pittet MJ, Batard P, Rufer N, de Smedt M, Guillaume P, et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 2002;195: 485-94.
24. Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distantmelanoma metastasis. J Clin Oncol 2012;30: 1835-41.
25. Khammari A, Labarriere N, Vignard V, Nguyen JM, Pandolfino MC, Knol AC, et al. Treatment of metastatic melanoma with autologous Melan-A/ MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol 2009;129: 2835-42.
26. Vignard V, Lemercier B, Lim A, Pandolfino MC, Guilloux Y, Khammari A, et al. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol 2005;175: 4797-805.
27. Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, et al. PD-1 expression conditions T cell avidity within an antigen-specific repertoire. Oncoimmunology 2016;5: e1104448.
28. Labarriere N, Fortun A, Bellec A, Khammari A, Dreno B, Saiagh S, et al. A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma. Clin Dev Immunol 2013;2013: 932318.
29. Hoos A, Eggermont AMM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102: 1388-97.
30. Bodinier M, Peyrat MA, Tournay C, Davodeau F, Romagne F, Bonneville M, et al. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nat Med 2000;6: 707-10.
31. Bouquie R, Bonnin A, Bernardeau K, Khammari A, Dreno B, Jotereau F, et al. A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes. Cancer Immunol Immunother 2009;58: 553-66.
32. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010;207: 2175-86.
33. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012;72: 887-96.
34. Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest 2015;125: 2046-58.
35. Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res 2014;20: 44-55.
36. Benlalam H, Labarriere N, Linard B, Derre L, Diez E, Pandolfino MC, et al. Comprehensive analysis of the frequency of recognition of melanomaassociated antigen(MAA)byCD8melanomainfiltratinglymphocytes (TIL): implications for immunotherapy. Eur J Immunol 2001;31: 2007-15.
37. Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph- Pietras D, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 2014;6: 254ra128.
38. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016;351: 1463-9.
39. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348: 69-74.
40. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. Tcell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017;545: 60-5.
41. Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28- dependent. Science 2017;355: 1423-7.
42. Lennerz V, FathoM, GentiliniC, Frye RA, LifkeA, Ferel D, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005;102: 16013-8.
43. Pinto S, Sommermeyer D, Michel C, Wilde S, Schendel D, Uckert W, et al. Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells. Eur J Immunol 2014;44: 2811-21.
44. Dietrich PY, Le Gal FA, Dutoit V, Pittet MJ, Trautman L, Zippelius A, et al. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol 2003;170: 5103-9.
45. Trautmann L, Labarriere N, Jotereau F, Karanikas V, Gervois N, Connerotte T, et al. Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol 2002;32: 3181-90.
46. Godet Y, Desfrancois J, Vignard V, Schadendorf D, Khammari A, Dreno B, et al. Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy. Eur J Immunol 2010;40: 1786-94.
47. Inozume T, Yaguchi T, Furuta J, Harada K, Kawakami Y, Shimada S. Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase. J Invest Dermatol 2016;136: 255-63.